Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 34, 329-343

Pharmacological Evaluation of Synthetic Cannabinoids Identified as Constituents of Spice

Affiliations

Pharmacological Evaluation of Synthetic Cannabinoids Identified as Constituents of Spice

Cornelius Hess et al. Forensic Toxicol.

Abstract

In recent years, many synthetic cannabinoid (CB) receptor agonists have appeared on the market as constituents of herbal incense mixtures known as "spice". Contrary to the declared use, they are perorally consumed as a replacement for marijuana to get "high". In many cases, detailed information on the physicochemical and pharmacological properties of the synthetic compounds found in spice preparations is lacking. We have now evaluated a large series of heterocyclic compounds, 1,3-disubstituted indole and 2-azaindole derivatives known or assumed to be CB1 receptor agonists, many of which have previously been identified in forensic samples. The mainly observed structural variations to circumvent restriction by law were bioisosteric exchanges of functional groups in known CB1 agonists. We analyzed the structure-activity relationships of compounds at human CB1 and CB2 receptors based on affinities obtained in radioligand binding studies, and determined their efficacy in cAMP accumulation assays. Moreover, we investigated the activities of the compounds at the orphan G protein-coupled receptors GPR18 and GPR55 both of which are known to interact with cannabinoids. Most of the investigated compounds behaved as potent full agonists of CB1 and CB2 receptors with affinities in the low nanomolar to subnanomolar concentration range. Some compounds were moderately potent GPR55 antagonists, while none interacted with GPR18. Most derivatives were predicted to cross the blood-brain barrier as determined by bioinformatics tools. These data are useful for assessing synthetic cannabinoids and will be helpful for predicting pharmacological properties of novel compounds that appear on the illicit drug market.

Keywords: GPR18; GPR55; Indazoles; Indoles; Structure-activity relationship; Synthetic cannabinoid.

Figures

Fig. 1
Fig. 1
Structures and affinities of standard CB receptor agonists
Fig. 2
Fig. 2
Functional properties of investigated compounds determined in cAMP accumulation assays, in the presence of forskolin (10 µM). Test concentration was 1 µM or 10 µM, depending on the determined K i value. The selected concentration corresponds to the concentration at which a maximal effect was observed. All experiments were carried out three to five times, each in duplicate. a Compounds 418; b compounds 1927; c compounds 2824. All results were normalized to maximal receptor activation by the full agonist CP55,940 (2)
Fig. 3
Fig. 3
Concentration-dependent inhibition of cAMP accumulation by XLR-12 (41). All experiments were carried out three to five times, each in duplicate
Fig. 4
Fig. 4
a Affinities of investigated compounds at the CB1 receptor plotted against logP values. b Affinities of investigated compounds at the CB2 receptor plotted against logP values

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles

References

    1. Fredriksson R, Lagerstrom MC, Lundin L, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63:1256–1272. doi: 10.1124/mol.63.6.1256. - DOI - PubMed
    1. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161–202. - PubMed
    1. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiat. 2001;178:101–106. doi: 10.1192/bjp.178.2.101. - DOI - PubMed
    1. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006;46:101–122. doi: 10.1146/annurev.pharmtox.46.120604.141254. - DOI - PubMed
    1. O’Keefe L, Simcocks AC, Hryciw DH, Mathai ML, McAinch AJ. The cannabinoid receptor 1 and its role in influencing peripheral metabolism. Diabetes Obes Metab. 2014;16:294–304. doi: 10.1111/dom.12144. - DOI - PubMed

LinkOut - more resources

Feedback